The shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) has been pegged with a rating of Overweight by JP Morgan in its latest research note that was published on June 15th, 2018. The research company has also assigned a $11 price target. JP Morgan wasn’t the only research firm that published a report of TherapeuticsMD, Inc., with other equities research analysts also giving their opinion on the stock. Morgan Stanley advised investors in its research note published on September 8th, 2017, to Equal-Weight the TXMD stock while also putting a $6 price target. The stock had earned Outperform rating from Oppenheimer when it published its report on July 11th, 2017. The stock was given Perform rating by Oppenheimer in its report released on May 9th, 2017. Jefferies was of a view that TXMD is Buy in its latest report on November 22nd, 2016 while giving it a price target of $18. Oppenheimer thinks that TXMD is worth Outperform rating. This was contained in the firm’s report on November 22nd, 2016.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 1 believe it has the potential for further growth, thus rating it as Hold while 2 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $14.57. The price of the stock the last time has raised by 59.49% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 50.34.
The shares of the company dipped by -1.93% during the trading session on Thursday, reaching a low of $5.59 while ending the day at $5.59. During the trading session, a total of 2.3 million shares were traded which represents a 30.26% incline from the average session volume which is 3.30M shares. TXMD had ended its last session trading at 5.70. TherapeuticsMD, Inc. currently has a market cap of $1.34B while its P/E earnings growth sits at 83.44, with a beta of 2.08. TherapeuticsMD, Inc. debt-to-equity ratio currently stands at 0.75, while its quick ratio hovers at 4.50. TXMD 52-week low price stands at $3.51 while its 52-week high price is $7.66.
The company in its last quarterly report recorded -$0.17 earnings per share which is below the -$0.17 predicted by most analysts. The TherapeuticsMD, Inc. generated $5.09 million in revenue during the last quarter, which is slightly higher than the $5.00 million predicted by analysts. In the second quarter last year, the firm recorded -$0.16 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 5.88%. TherapeuticsMD, Inc. has the potential to record -0.59 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Imperial Capital published a research note on February 7th, 2019 where it informed investors and clients that Arlo Technologies, Inc. (NYSE:ARLO) is now rated as Outperform. Their price target on the stock stands at $7.50. Morgan Stanley also rated ARLO as Initiated on September 8th, 2017, with its price target of $44 suggesting that ARLO could surge by 38.86% from its current share price. Even though the stock has been trading at $4.31/share, analysts expect it to surge higher by -0.70% to reach $7.00/share. It started the day trading at $4.3 and traded between $4.03 and $4.28 throughout the trading session.
At the moment, only of Arlo Technologies, Inc. shares were sold short. The company’s average trading volume currently stands at 2.81M shares, which means that the short-interest ratio is just 2.39 days. Over the past seven days, the company moved, with its shift of -1.83%. Looking further, the stock has dropped -56.59% over the past 90 days while it lost -77.08% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Fidelity Management Research Co bought more ARLO shares, increasing its portfolio by +30.25% during the last quarter. This move now sees Fidelity Management Research Co purchasing 1,724,211 shares in the last quarter, thus it now holds 7,424,338 shares of ARLO, with a total valuation of $32,147,384. PRIMECAP Management Co followed the path by increasing its ARLO portfolio by +39.11% in the quarter. This means that PRIMECAP Management Co bought 1,319,414 shares in the last quarter and now controls 4,692,700 shares of the ARLO stock, with the valuation hitting $20,319,391.
Similarly, Macquarie Investment Management B increased its Arlo Technologies, Inc. shares by +27.18% during the recently filed quarter. Following these latest developments, around 0.70% of Arlo Technologies, Inc. stocks are owned by institutional investors and hedge funds.